Search

Market Outlook-Leveraging Market Corrections for M&A or IPOs

MARKET OUTLOOK-LEVERAGING MARKET CORRECTIONS FOR M&A OR IPOS

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of heightened market volatility. Investors'...

Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More

BIO ROUNDUP: NEW CRISPR FEUD, A NY SPLASH, PHARMA VS. CONGRESS & MORE

If you're into congressional spectacles, stay tuned later this month. A group of top biopharma executives-the full roster isn't known...

 
 
 
Using Decision Science for Negotiations: Getting to Win-Win

USING DECISION SCIENCE FOR NEGOTIATIONS: GETTING TO WIN-WIN

New medicines often progress from idea to regulatory approval through collaborative licensing agreements or acquisition. Deal-making...

Former Insys execs in alleged opioid conspiracy start criminal trial in Boston

FORMER INSYS EXECS IN ALLEGED OPIOID CONSPIRACY START CRIMINAL TRIAL IN BOSTON

The trial - of Insys founder John Kapoor and four other defendants - had been scheduled to start Monday morning. Two other executives...

 
 
 
Novartis stockpiles drugs amid Brexit supply chain concerns

NOVARTIS STOCKPILES DRUGS AMID BREXIT SUPPLY CHAIN CONCERNS

The Swiss drugmaker is concerned that a no-deal Brexit would disrupt delicate supply chains and urged the UK and EU to provide clarity...

Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

NOTES FROM THE JPM19 VORTEX: PRICE APOCALYPSE, CELGENE FALLOUT & MORE

[ Editor's note: Ben Fidler and Sarah de Crescenzo coauthored this report .] It is here, and then it is gone. But by the time everyone...

 
 
 
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

BIO ROUNDUP: $74B FOR CELGENE, TWO CAR-T TALES, READY FOR SF & MORE

In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy,...

 
 
 
Bristol-Myers Squibb to acquire Celgene in $74B deal

BRISTOL-MYERS SQUIBB TO ACQUIRE CELGENE IN $74B DEAL

The acquisition brings together two of the largest drugmakers in the country, both of which are major players in biopharma, particularly...

SENIOR PROJECT ENGINEER, BIOPHARMA ENGINEERING - LAGUNA SOURCE - SAN DIEGO, CA

6+ years of BioPharma, BioPharmaceutical, Pharmaceutical or Biotechnology industry experience. This is a stellar opportunity within...

 
 
 

LEAD MAINTENANCE MECHANIC - 1129 - TANVEX BIOPHARMA USA,INC - SAN DIEGO, CA

The Lead Maintenance Mechanic must be detail oriented and be able to complete any required GMP documentation in a timely manner, including...

 
 
 
OncoMed's Saga Ends in Reverse Merger with UK-Based Mereo BioPharma

ONCOMED'S SAGA ENDS IN REVERSE MERGER WITH UK-BASED MEREO BIOPHARMA

OncoMed Pharmaceuticals attracted hundreds of millions of dollars from investors and pharmaceutical partners with compounds it developed...

Biopharma needs a new R&D, innovation model

BIOPHARMA NEEDS A NEW R&D, INNOVATION MODEL

Strategic partnerships are one way for biopharmaceutical companies to expand capabilities and offerings and proactively define their...

 
 
 
Bio Roundup: Alzheimer's Puzzle, ESMO Assessed, Drug Prices & More

BIO ROUNDUP: ALZHEIMER'S PUZZLE, ESMO ASSESSED, DRUG PRICES & MORE

In the biotech investment and research communities this week, much of the attention was turned to Europe. Munich, Germany, hosted the...

 
 
 
BIO Investor Forum Explores “Digiceuticals” as a New Class of FDA-Approved Therapeutics

BIO INVESTOR FORUM EXPLORES “DIGICEUTICALS” AS A NEW CLASS OF FDA-APPROVED THERAPEUTICS

Within the past year, the FDA has launched a provider pre-certification program as a pilot to manage the expansion of “digiceuticals”...

2018 BIO Investor Forum Wraps Up

2018 BIO INVESTOR FORUM WRAPS UP

As the stock market continued its volatile swings this week, investors at the BIO Investor Forum -which wrapped up today in San Francisco-seemed...

 
 
 
Bio Roundup: Amarin's Stunner, Lung Cancer News, Data Dumps & More

BIO ROUNDUP: AMARIN'S STUNNER, LUNG CANCER NEWS, DATA DUMPS & MORE

Six years ago, a biotech called Amarin won FDA approval of a prescription fish-oil pill, Vascepa, because it could lower triglycerides,...

Principia Sets IPO Terms as It Eyes Late-Stage Studies for Lead Drug

PRINCIPIA SETS IPO TERMS AS IT EYES LATE-STAGE STUDIES FOR LEAD DRUG

Principia Biopharma plans to sell 4.6 million shares priced between $15 and $17 apiece when the rare disease drug developer makes its...